Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop anti-CD112 therapeutic monoclonal antibody program together. Our scientists are dedicated to bringing together years of valuable experience to our partner and achieve a meaningful partnership. By doing so, we wish to help both parties to proceed with IND and many stages of clinical trials beyond. Learn more: Next-IO™ Anti-CD112 Therapeutic Monoclonal Antibody Program